Acadia Pharmaceuticals | ACAD - Gross Profit On Sales


Acadia Pharmaceuticals reported $243.27M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Cytokinetics USD 19.2M 1.44M Mar/2026
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
J&J USD 17.24B 642M Mar/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Prothena USD 21K 2.39M Dec/2025
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026